EUVIMEDEUVIMED entdecken
Open Access

Engineered Probiotic Saccharomyces boulardii Reduces Colitis-Associated Colorectal Cancer Burden in Mice

Tyler Culpepper, Krithika Senthil, Jessica Vlcek, Anthony Hazelton, Mairead K Heavey, Rani S Sellers, Juliane Nguyen, Janelle C Arthur

Digestive Diseases and Sciences · 2025-07 · 70 (7) · 2348-2367

DOI: 10.1007/s10620-025-09008-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestive Diseases and Sciences, online erschienen am 29.03.2025. Verfasst von Tyler Culpepper und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC…. Hauptthemen laut MEDLINE: Probiotics, Saccharomyces boulardii, Colitis-Associated Neoplasms, Colitis. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIH HHS, National Institutes of Health,United States.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Individuals with inflammatory bowel diseases experience an elevated risk of colorectal cancer driven by chronic inflammation. Current systemic immunosuppressive therapies often cause severe side effects. Live oral biotherapeutics are an emerging treatment modality that directly target the intestines. We have engineered a probiotic Saccharomyces boulardii strain that expresses targeting ligands to bind fibronectin on inflamed mucosa and secretes anti-tumor necrosis factor nanobodies locally to reduce inflammation. We previously demonstrated that engineering S. boulardii to bind fibronectin enhanced colonization and reduced inflammation in a DSS colitis model. AIMS: Here, we tested the anti-cancer potential of engineered S. boulardii using a well-established model of IBD-associated CRC, azoxymethane-treated interleukin 10-deficient (AOM/Il10-/-) mice. These mice develop inflammation and invasive tumors that model those found in inflammatory bowel disease. METHODS: Mice were orally administered engineered S. boulardii at two dosing frequencies, unmodified S. boulardii, or placebo throughout the 18-week model. Colons were harvested for gross, histological, and molecular evaluation for inflammation and tumorigenesis. RESULTS: Histological colon inflammation was reduced by twice weekly dosing of engineered and unmodified S. boulardii. Engineered S. boulardii reduced gross tumor number in a dose-dependent manner, with median tumor counts reduced from 7.5 to 2 per mouse (p < 0.0002 vs. placebo). Unmodified S. boulardii similarly reduced gross tumor number. Colonization studies revealed that engineered S. boulardii failed to colonize for greater time or density vs. unmodified S. boulardii. CONCLUSION: Together our data indicate that engineering S. boulardii does not reduce its ability to decrease inflammation-associated tumorigenesis, and that further host-binding target optimization is required to enhance colonization and anti-cancer effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProbioticsSaccharomyces boulardiiColitis-Associated NeoplasmsColitisColorectal NeoplasmsAnimalsMiceMice, Inbred C57BLDisease Models, AnimalAzoxymethaneMice, KnockoutTumor Burden

Stichwörter der Autor:innen

Colitis-associated cancerColorectal cancerInflammatory bowel diseasesLive biotherapeuticProbioticSaccharomyces boulardii

Substanzen

Azoxymethane

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Department of Nutrition, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Division of Comparative Medicine, Department of Pathology and Laboratory Medicine, School Or Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Department of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. janelle_arthur@med.unc.edu.
  • Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. janelle_arthur@med.unc.edu.

Förderung

  • NIDDK NIH HHS
  • NIH HHS
  • National Institutes of Health,United States
  • National Institutes of Health

Zitieren

APA

Culpepper, T., Senthil, K., Vlcek, J., Hazelton, A., Heavey, M. K., Sellers, R. S., Nguyen, J., & Arthur, J. C. (2025). Engineered Probiotic Saccharomyces boulardii Reduces Colitis-Associated Colorectal Cancer Burden in Mice. Digestive Diseases and Sciences, 70(7), 2348-2367. https://doi.org/10.1007/s10620-025-09008-9

Vancouver

Culpepper T, Senthil K, Vlcek J, Hazelton A, Heavey MK, Sellers RS, et al. Engineered Probiotic Saccharomyces boulardii Reduces Colitis-Associated Colorectal Cancer Burden in Mice. Digestive Diseases and Sciences. 2025;70(7):2348-2367. doi:10.1007/s10620-025-09008-9

BibTeX
@article{Culpepper2025,
  author = {Culpepper, Tyler and Senthil, Krithika and Vlcek, Jessica and Hazelton, Anthony and Heavey, Mairead K and Sellers, Rani S and Nguyen, Juliane and Arthur, Janelle C},
  title = {Engineered Probiotic Saccharomyces boulardii Reduces Colitis-Associated Colorectal Cancer Burden in Mice},
  journal = {Digestive Diseases and Sciences},
  year = {2025},
  volume = {70},
  number = {7},
  pages = {2348--2367},
  doi = {10.1007/s10620-025-09008-9}
}
Kostenlos starten →